Ecolab Inc (ECL)vsVersamet Royalties Corporation Common Stock (VMET)
ECL
Ecolab Inc
$285.17
+0.60%
BASIC MATERIALS · Cap: $79.69B
VMET
Versamet Royalties Corporation Common Stock
$10.25
+5.13%
BASIC MATERIALS · Cap: $933.87M
Smart Verdict
WallStSmart Research — data-driven comparison
Ecolab Inc generates 30370% more annual revenue ($16.84B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 12.6%. VMET trades at a lower P/E of 28.7x. VMET earns a higher WallStSmart Score of 60/100 (C+).
ECL
Buy53
out of 100
Grade: C-
VMET
Buy60
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Keeps 58 of every $100 in revenue as profit
Strong operational efficiency at 90.6%
Revenue surging 594.0% year-over-year
Earnings expanding 573.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
3.3% earnings growth
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ECL
The strongest argument for ECL centers on Market Cap, Return on Equity.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.
Bear Case : ECL
The primary concerns for ECL are P/E Ratio, EPS Growth, Piotroski F-Score.
Bear Case : VMET
The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
ECL profiles as a value stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 594.0% — sustainability is the question.
ECL generates stronger free cash flow (97M), providing more financial flexibility.
Monitor SPECIALTY CHEMICALS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VMET scores higher overall (60/100 vs 53/100), backed by strong 58.4% margins and 594.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ecolab Inc
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.
Versamet Royalties Corporation Common Stock
BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA
Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.
Compare with Other SPECIALTY CHEMICALS Stocks
Want to dig deeper into these stocks?